Felodipine calcium channel blockers

Description Results

all-cause death 1.08 [0.67; 1.73]

all-cause death 1.35 [0.23; 7.95]

felodipine 5mg twice daily (n=224)

vs.

placebo (n=226)

Double blind

Parallel groups

Sample size: 224/226

Primary endpoint: exercise tolerance

FU duration: mean 18mo (range 3-39 mo)

felodipine 10 mg twice daily (n=18)

vs.

placebo (n=18)

Double blind

Cross over

Sample size: 18/18

Primary endpoint: haemodynamic

FU duration: 3 weeks

felodipine extended release 2.5-10mg twice daily (in addition to existing background medication) for 12 weeks (n=132)

vs.

placebo (n=119)

Double blind

Parallel groups

Sample size: 132/119

Primary endpoint: exercise tolerance

FU duration: 3 months

felopidine 10 mg BID (n=10)

vs.

placebo (n=10)

Double blind

Parallel groups

Sample size: 10/10

Primary endpoint: haemodynamic

FU duration: 6 months

felodipine 10 mg b.i.d. (n=9)

vs.

enalapril 10 mg b.i.d. (n=11)

Double blind

Sample size: 9/11

Primary endpoint: cardiopulmonary exercise tests

FU duration: 4 months

felodipine 2.5mg twice daily (n=22)

vs.

enalapril 2.5mg twice daily (n=24)

Double blind

Parallel groups

Sample size: 22/24

Primary endpoint: cardiopulmonary exercise tests

FU duration: 4 months